CClinicalTrials.gg
CompletedNCT04834843COPE registryUpdated Apr 8, 2021

Temporal Trends of COronary Artery Disease and PEripheral Artery Disease (COPE) in Korea

An observational study in Coronary Artery Disease, Peripheral Artery Disease and Cardiovascular Diseases, sponsored by Wonju Severance Christian Hospital. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-04-08.

Sponsored by Wonju Severance Christian Hospital · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
700,000
Ages
18 Years and older
Sex
All
01

Study summary

Cardiovascular disease (CVD) is caused by atherosclerosis of the artery and is classified into coronary artery disease, cerebrovascular disease, and peripheral arterial disease, depending on the location of the artery and the target organs. However, since CVD share a similar pathophysiology and the probability of incidence of other CVD in CVD patients is very high. It is thought that CVD incidence and mortality can be reduced by predicting the degree of incidence of other CVD in CVD patients. The aim of this study is to investigate the incidence and mortality of other CVD diseases in CVD patients.

02

Conditions studied

03

In context

Cardiovascular Diseases

4,904 studies on the registry are indexed under Cardiovascular Diseases; 919 are open to participants now.

This study's enrollment of 700,000 is above the median of 573 across 1,485 observational studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

Wonju Severance Christian Hospital is the lead sponsor of 41 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

People aged at least 18 years old with CAD, PAD, or cerebrovascular disease were identified from Korean national health insurance using International Classification of Diseases, tenth revision (ICD-10) codes.

Inclusion criteria

  • Koreans who diagnosed with coronary artery disease between 2009 and 2018
  • Koreans who diagnosed with peripheral artery disease between 2009 and 2018
  • Koreans who diagnosed with cerebrovascular disease between 2009 and 2018
  • more than 18 years old

Exclusion criteria

Exclusion Criteria:

  • less than 18 years old
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
700,000 participants (actual)
Patient registry
No

Interventions

  • OtherObservational study, no intervention

    Observational study, no intervention

06

What researchers measure

Primary outcomes

  1. Incidence of coronary artery disease, cerebrovascular disease, peripheral arterial disease

    Among all Koreans, percentage (%) of patients with a history of being diagnosed with CVD and underwent in-hospital treatment

    Time frame: Up to 10 years

Secondary outcomes

  1. 1-year mortality

    The percentage (%) of any CVD related mortality

    Time frame: Up to 1 year

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Sundaram V, Bloom C, Zakeri R, Halcox J, Cohen A, Bowrin K, Briere JB, Banerjee A, Simon DI, Cleland JGF, Rajagopalan S, Quint JK. Temporal trends in the incidence, treatment patterns, and outcomes of coronary artery disease and peripheral artery disease in the UK, 2006-2015. Eur Heart J. 2020 May 1;41(17):1636-1649. doi: 10.1093/eurheartj/ehz880. PubMed 31883328 ↗
  • Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, Goto S, Liau CS, Richard AJ, Rother J, Wilson PW; REACH Registry Investigators. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006 Jan 11;295(2):180-9. doi: 10.1001/jama.295.2.180. PubMed 16403930 ↗
  • Ahn S, Park YJ, Min SI, Kim SY, Ha J, Kim SJ, Kim HS, Yoon BW, Min SK. High prevalence of peripheral arterial disease in Korean patients with coronary or cerebrovascular disease. J Korean Med Sci. 2012 Jun;27(6):625-9. doi: 10.3346/jkms.2012.27.6.625. Epub 2012 May 26. PubMed 22690093 ↗
  • Sogaard M, Nielsen PB, Skjoth F, Eldrup N, Larsen TB. Temporal Changes in Secondary Prevention and Cardiovascular Outcomes After Revascularization for Peripheral Arterial Disease in Denmark: A Nationwide Cohort Study. Circulation. 2021 Mar 2;143(9):907-920. doi: 10.1161/CIRCULATIONAHA.120.047994. Epub 2020 Dec 10. PubMed 33300375 ↗

Individual participant data

Plan to share: No — The IPD from Korean national health insurance is not publicly accessible due to Korean personal information projection act

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 8, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04834843
Lead sponsor
Wonju Severance Christian Hospital
Responsible party
Dong-Hyuk Cho (Assistant professor, Wonju Severance Christian Hospital) — Principal investigator
First posted
Apr 8, 2021
Start date
Jan 1, 2009
Primary completion
Dec 31, 2018
Completion
Dec 31, 2020
Last update
Apr 8, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion